These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36245381)
21. Making the Case for Accelerated Withdrawal of Aducanumab. Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287 [TBL] [Abstract][Full Text] [Related]
22. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle. Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697 [TBL] [Abstract][Full Text] [Related]
23. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491 [TBL] [Abstract][Full Text] [Related]
24. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. Ross EL; Weinberg MS; Arnold SE JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024 [TBL] [Abstract][Full Text] [Related]
28. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease. Heidebrink JL; Paulson HL Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515 [TBL] [Abstract][Full Text] [Related]
29. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243 [TBL] [Abstract][Full Text] [Related]
30. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Høilund-Carlsen PF; Alavi A J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891 [TBL] [Abstract][Full Text] [Related]
31. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. Herder M J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277 [TBL] [Abstract][Full Text] [Related]
32. FDA's dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps. Rizk JG; Lewin JC BMJ Evid Based Med; 2023 Apr; 28(2):78-82. PubMed ID: 35450946 [TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis. Terao I; Honyashiki M; Inoue T Ageing Res Rev; 2022 Nov; 81():101709. PubMed ID: 35961514 [TBL] [Abstract][Full Text] [Related]
34. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1. de la Torre JC; Gonzalez-Lima F J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943 [No Abstract] [Full Text] [Related]
35. Aducanumab for the treatment of Alzheimer's disease: a systematic review. Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284 [TBL] [Abstract][Full Text] [Related]
36. A Bayesian perspective on Biogen's aducanumab trial. Temp AGM; Ly A; van Doorn J; Wagenmakers EJ; Tang Y; Lutz MW; Teipel S Alzheimers Dement; 2022 Nov; 18(11):2341-2351. PubMed ID: 35235700 [TBL] [Abstract][Full Text] [Related]
37. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development. Brockmann R; Nixon J; Love BL; Yunusa I Lancet Reg Health Am; 2023 Apr; 20():100467. PubMed ID: 36908502 [TBL] [Abstract][Full Text] [Related]